$PRQR Announces Positive Results from Clinical Trial of QR-421a
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)
QR-421a observed to be well tolerated with no serious adverse events reported
Two pivotal Phase 2/3 trials are expected to start by the end of 2021
finance.yahoo.com/ne...nical-110000726.html
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)
QR-421a observed to be well tolerated with no serious adverse events reported
Two pivotal Phase 2/3 trials are expected to start by the end of 2021
finance.yahoo.com/ne...nical-110000726.html
Bình luận:
Citigroup Reiterated buy $33 → $44